Sangamo Therapeutics, Inc. (SGMO)
NASDAQ: SGMO · Real-Time Price · USD
0.7870
-0.0279 (-3.42%)
At close: Apr 25, 2025, 4:00 PM
0.7870
0.00 (0.00%)
Pre-market: Apr 28, 2025, 5:54 AM EDT
Sangamo Therapeutics Revenue
In the year 2024, Sangamo Therapeutics had annual revenue of $57.80M, down -67.20%. Sangamo Therapeutics had revenue of $7.55M in the quarter ending December 31, 2024, with 269.78% growth.
Revenue (ttm)
$57.80M
Revenue Growth
-67.20%
P/S Ratio
2.75
Revenue / Employee
$315,847
Employees
183
Market Cap
176.85M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 57.80M | -118.43M | -67.20% |
Dec 31, 2023 | 176.23M | 64.93M | 58.34% |
Dec 31, 2022 | 111.30M | 598.00K | 0.54% |
Dec 31, 2021 | 110.70M | -7.49M | -6.34% |
Dec 31, 2020 | 118.19M | 15.76M | 15.39% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
SGMO News
- 23 days ago - Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal - Seeking Alpha
- 24 days ago - Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Business Wire
- 5 weeks ago - Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Business Wire
- 7 weeks ago - Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference - Business Wire
- 2 months ago - Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - Business Wire
- 3 months ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sangamo Therapeutics, Inc. (SGMO) And Encourages Shareholders to Reach Out - Accesswire
- 3 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sangamo Therapeutics, Inc. (SGMO) and Encourages Shareholders to Learn More About the Investigation - Accesswire